Nevro (NVRO) 2024 Truist Securities MedTech Conference summary

Strategic initiatives and leadership changes

• Refinanced debt and completed the first acquisition to diversify into mechanical back pain with SI joint fusion devices.

• Restructured operations, reducing expenses by over $30 million without impacting sales and marketing.

• Brought in about half a new leadership team to strengthen execution.

• Focus remains on commercial execution, business diversification, and achieving profitability.

Market performance and growth drivers

• Achieved 6% worldwide growth in the last quarter, outperforming most competitors in the SCS market.

• Early stages of benefiting from a replacement cycle for rechargeable batteries, expected to be a future tailwind.

• PDN (painful diabetic neuropathy) and nonsurgical back pain are key growth drivers, with PDN market penetration under 1%.

• Product innovation and R&D pipeline are expected to drive further diversification and market share gains.

Competitive landscape and innovation

• Closed-loop technology is not seen as necessary due to the company's high-frequency, paresthesia-free approach.

• High-frequency SCS is positioned as a competitive advantage, especially for diabetic neuropathy patients.

• New product launches and FDA approvals by competitors are viewed as positive for overall market growth.